ABUS vs TT
Arbutus Biopharma Corp (ABUS) versus Trane Technologies plc (TT) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TT revenue for 2025-12-31 was $21.32B. Net income was $2.92B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. TT currently screens at market cap $104.45B and trailing P/E 36.2.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Not investment advice. Open the ABUS and TT stock pages for the full models.
Not investment advice.